Reprogramming cells from Gulf War veterans into neurons to study Gulf War illness
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Gulf War illness (GWI), which afflicts at least 25% of veterans who served in the 1990–1991 war in the Persian Gulf, is thought to be caused by deployment exposures to various neurotoxicants, including pesticides, anti–nerve gas pills, and low-level nerve agents including sarin/cyclosarin. GWI is a multisymptom disorder characterized by fatigue, joint pain, cognitive problems, and gastrointestinal complaints. The most prominent symptoms of GWI (memory problems, poor attention/concentration, chronic headaches, mood alterations, and impaired sleep) suggest that the disease primarily affects the CNS. Development of urgently needed treatments depends on experimental models appropriate for testing mechanistic hypotheses and for screening therapeutic compounds. Rodent models have been useful thus far, but are limited by their inability to assess the contribution of genetic or epigenetic background to the disease, and because disease-vulnerable proteins and pathways may be different in humans relative to rodents. As of yet, no postmortem tissue from the veterans has become available for research. We are moving forward with a paradigm shift in the study of GWI, which utilizes contemporary stem cell technology to convert somatic cells from Gulf War veterans into pluripotent cell lines that can be differentiated into various cell types, including neurons, glia, muscle, or other relevant cell types. Such cell lines are immortal and will be a resource for GWI researchers to pursue mechanistic hypotheses and therapeutics.
GLOSSARY
- DFP=
- di-isopropyl fluorophosphates;
- GW=
- Gulf War;
- GWI=
- Gulf War illness;
- GWIC=
- Gulf War Illness Consortium;
- hiN=
- human induced neurons;
- hiPSC=
- human induced pluripotent stem cells;
- OP=
- organophosphate;
- PB=
- pyridostigmine bromide
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received September 30, 2016.
- Accepted in final form February 23, 2017.
- © 2017 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- GLOSSARY
- WHAT DO WE KNOW ABOUT GWI FROM RODENT MODELS AND CLINICAL STUDIES?
- HUMAN INDUCED NEURONS—BRIDGING THE GAP WITH A PARADIGM SHIFT
- RECRUITMENT PROCESS AND INFORMED CONSENT
- CONTROL SAMPLES
- EXPERIMENTAL PARADIGM
- A NOTE TO PHYSICIANS
- AUTHOR CONTRIBUTIONS
- STUDY FUNDING
- DISCLOSURE
- ACKNOWLEDGMENT
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Excess incidence of ALS in young Gulf War veteransRobert W. Haley et al.Neurology, September 22, 2003 -
Articles
Occurrence of amyotrophic lateral sclerosis among Gulf War veteransR.D. Horner, K.G. Kamins, J.R. Feussner et al.Neurology, September 22, 2003 -
Articles
Neurophysiologic analysis of neuromuscular symptoms in UK Gulf War veteransA controlled studyM. K. Sharief, J. Priddin, R. S. Delamont et al.Neurology, November 26, 2002 -
Articles
Clinical and laboratory assessment of distal peripheral nerves in Gulf War veterans and spousesL. E. Davis, S. A. Eisen, F. M. Murphy et al.Neurology, September 27, 2004